Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001641172-25-007922
Filing Date
2025-05-01
Accepted
2025-04-30 17:33:02
Documents
22
Period of Report
2025-04-30

Document Format Files

Seq Description Document Type Size
1 DEF 14A formdef14a.htm   iXBRL DEF 14A 472935
2 GRAPHIC formdef14a_001.jpg GRAPHIC 9727
3 GRAPHIC formdef14a_002.jpg GRAPHIC 2631
4 GRAPHIC formdef14a_003.jpg GRAPHIC 2629
5 GRAPHIC formdef14a_004.jpg GRAPHIC 2533
6 GRAPHIC formdef14a_005.jpg GRAPHIC 3302
7 GRAPHIC formdef14a_006.jpg GRAPHIC 892407
8 GRAPHIC formdef14a_007.jpg GRAPHIC 510181
  Complete submission text file 0001641172-25-007922.txt   4064389

Data Files

Seq Description Document Type Size
9 XBRL SCHEMA FILE kapa-20241231.xsd EX-101.SCH 3428
10 XBRL DEFINITION FILE kapa-20241231_def.xml EX-101.DEF 5351
11 XBRL LABEL FILE kapa-20241231_lab.xml EX-101.LAB 53093
12 XBRL PRESENTATION FILE kapa-20241231_pre.xml EX-101.PRE 41488
25 EXTRACTED XBRL INSTANCE DOCUMENT formdef14a_htm.xml XML 1803
Mailing Address 2355 WESTWOOD BLVD. #139 LOS ANGELES CA 90064
Business Address 2355 WESTWOOD BLVD. #139 LOS ANGELES CA 90064 818-404-5541
Kairos Pharma, LTD. (Filer) CIK: 0001962011 (see all company filings)

EIN.: 462993314 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-42275 | Film No.: 25897759
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)